CellSource Co

CellSource Co Receivables

The Accounts Receivable of CellSource Co (4880.T) as of Oct 28, 2026 is 332.67 M JPY. In the previous year, Accounts Receivable was 323.52 M JPY — a change of 2.83% (higher).

Receivables

332.67 MJPY

YoY

2.83%

Last updated:

Accounts Receivable of CellSource Co is 2025 332.67 M JPY. Accounts Receivable of CellSource Co was 2024 323.52 M JPY. It decreases by 2.83% higher compared to the previous year.

The CellSource Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
136.59 M JPY
Jan 1, 2019
134.17 M JPY
Jan 1, 2020
224.92 M JPY
Jan 1, 2021
307.43 M JPY
Jan 1, 2022
649.80 M JPY
Jan 1, 2023
361.49 M JPY
Jan 1, 2024
323.52 M JPY
Jan 1, 2025
332.67 M JPY
The CellSource Co Receivables history
YEARReceivablesYoY
332.67 MJPY+2.83%
323.52 MJPY-10.50%
361.49 MJPY-44.37%
649.80 MJPY+111.36%
307.43 MJPY+36.69%
224.92 MJPY+67.63%
134.17 MJPY-1.77%
136.59 MJPY+173.70%
49.91 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Accounts Receivable of CellSource Co is 332.67 M JPY in 2025.

Accounts Receivable of CellSource Co changed from 323.52 M JPY to 332.67 M JPY, representing a 2.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable CellSource Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — CellSource Co

All Key Metrics — CellSource Co